Liu Yi, Zhang Na, Cao Quanjun, Cui Xuejie, Zhou Qiaoling, Yang Chengxiang
LinZi People's Hospital, Linzi, Shandong, China.
LinZi People's Hospital, Linzi, Shandong, China.
Biomed Pharmacother. 2017 Jun;90:47-52. doi: 10.1016/j.biopha.2017.03.041. Epub 2017 Mar 22.
Studies on the effects of propofol on the growth of hepatoma xenografts in Balb/c mice.
In an effort to establish a hepatoma-xenograft model of BALB/C mice, human hepatocellular carcinoma cells SMMC-7721 were inoculated subcutaneously into BALB/C mice. Forty mice were randomly divided into five different groups (n=8): control group (C group), Intralipid group (Y group), low dose (50mg/kg) propofol group (P group), medium dose (100mg/kg) propofol group (P group) and high dose (150mg/kg) propofol group (P group). The tumor volume was measured before treatment and every 3days after treatment (T-T, T represents time point before treatment, T-T represent time points every 3days after treatment for a total of 18 days). All mice were sacrificed 19days after drug withdrawal. The tumor masses were extracted, weighed, and the tumor inhibition rate of propofol was calculated. The protein levels of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in the xenografted tumors were analyzed by immunohistochemistry staining.
No statistical significance in the tumor volume at T (before treatment), T (3days after treatment), and T (6days after treatment) among the five groups (P>0.05) could be determined. Compared to group C, the tumor volumes in the P, P, and P groups were found to be significantly decreased in size upon increasing the propofol dosages (P<0.05). There was no statistical significance at time points T-T in group Y compared to group C (P>0.05). The tumor weights in the P, P, and P groups were found to be significantly lower as the propofol dosages increased (P<0.05), with no statistical significance determined in group Y (P>0.05). MMP-2 and VEGF protein levels were found to be significantly lower in the P, P, and P groups as the propofol dosages increased (P<0.05), with no statistical significance in group Y (P>0.05).
Within a certain range, propofol was found to inhibit tumor growth and expression of MMP-2 and VEGF proteins in hepatoma xenografts in BALB/C mice in a dose-dependent manner.
研究丙泊酚对Balb/c小鼠肝癌异种移植瘤生长的影响。
为建立BALB/C小鼠肝癌异种移植瘤模型，将人肝癌细胞SMMC-7721皮下接种于BALB/C小鼠。40只小鼠随机分为5组（n = 8）：对照组（C组）、脂肪乳剂组（Y组）、低剂量（50mg/kg）丙泊酚组（P组）、中剂量（100mg/kg）丙泊酚组（P组）和高剂量（150mg/kg）丙泊酚组（P组）。在治疗前及治疗后每3天测量肿瘤体积（T-T，T代表治疗前时间点，T-T代表治疗后每3天的时间点，共18天）。所有小鼠在停药19天后处死。取出肿瘤块，称重，并计算丙泊酚的肿瘤抑制率。通过免疫组织化学染色分析异种移植瘤中基质金属蛋白酶-2（MMP-2）和血管内皮生长因子（VEGF）的蛋白水平。
五组在T（治疗前）、T（治疗后3天）和T（治疗后6天）时的肿瘤体积无统计学差异（P>0.05）。与C组相比，随着丙泊酚剂量增加，P、P和P组的肿瘤体积显著减小（P<0.05）。Y组在T-T时间点与C组相比无统计学差异（P>0.05）。随着丙泊酚剂量增加，P、P和P组的肿瘤重量显著降低（P<0.05），Y组无统计学差异（P>0.05）。随着丙泊酚剂量增加，P、P和P组中MMP-2和VEGF蛋白水平显著降低（P<0.05），Y组无统计学差异（P>0.05）。
在一定范围内，丙泊酚呈剂量依赖性抑制Balb/c小鼠肝癌异种移植瘤的生长及MMP-2和VEGF蛋白的表达。
